Peter Ellmark
Medicon Village
Lund, M, Sweden
Lund, M, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer.
Journal: Nature communications
Published: May 09, 2025
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1.
Journal: Cell reports. Medicine
Published: February 21, 2025
ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell-Dependent Tumor Immunity and Synergizes with PD-1 Blockade.
Journal: Cancer immunology research
Published: January 31, 2025
First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies.
Journal: Journal for immunotherapy of cancer
Published: December 14, 2024
Next-generation CD40 agonists for cancer immunotherapy.
Journal: Expert opinion on biological therapy
Published: May 20, 2024
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study.
Journal: The Lancet. Oncology
Published: April 11, 2024
Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes.
Journal: Cells
Published: April 11, 2024
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1.
Journal: Cancer immunology, immunotherapy : CII
Published: August 06, 2023
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
Journal: Journal for immunotherapy of cancer
Published: September 30, 2022
Last Updated: 09/26/2026